Clinical Trials for Brain Tumor

Targeting Macrophage Migration Inhibitory Factor: A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with progressive WHO grade 4 gliomas undergoing planned resection and eligible for postoperative chemotherapy receive sitagliptin (DPP-4 inhibitor targeting MDSC trafficking/function) given preoperatively in most patients and then continued with standard chemotherapy postoperatively. Aims to increase intratumoral CD8+ T-cell infiltration and assess PFS/OS and safety; excludes patients with prior gliptin use or uncontrolled diabetes requiring insulin/sulfonylureas.

ClinicalTrials.gov ID: NCT07003542

Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments

TrialFetch AI summary: Children, adolescents, and young adults (≤21 years) with relapsed or refractory solid or hematologic malignancies and accessible tumor tissue undergo ex vivo drug sensitivity testing integrated with genomic profiling to guide individualized therapy selection. Treating physicians may use matched, typically approved monotherapies or combinations based on predicted sensitivity; outcomes are compared with contemporaneous patients receiving non–FPM standard-of-care therapy.

ClinicalTrials.gov ID: NCT05857969

A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide

TrialFetch AI summary: Adults with IDH–wild type recurrent/progressive malignant glioma (GBM or related high-grade gliomas) with a 1–2 cm non-eloquent, enhancing lesion receive stereotactic intratumoral injections of rQNestin34.5v.2 (CAN-3110), an oncolytic HSV-1 engineered for nestin-expressing glioma selectivity (ICP34.5 under nestin promoter; attenuated ICP6), with cohorts including single-dose, single-dose plus short-course cyclophosphamide pre-treatment, or repeat dosing. Key exclusions include multifocal/eloquent/brainstem disease, active infections or significant immunosuppression, recent anti-VEGF therapy, and inability to pause anticoagulation.

ClinicalTrials.gov ID: NCT03152318

A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

TrialFetch AI summary: For pediatric and adult patients with relapsed/refractory high-risk neuroblastoma/ganglioneuroblastoma or osteosarcoma, after standard therapies. Patients receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous GD2-directed CAR T cells engineered to co-express IL-15 (to enhance persistence/function) and an inducible caspase-9 safety switch.

ClinicalTrials.gov ID: NCT03721068

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases

TrialFetch AI summary: Adults with solid tumor brain metastases (ECOG 0–1, no prior WBRT, no leptomeningeal disease) receive upfront pulsed reduced dose-rate whole-brain radiation therapy (30 Gy/10 fx) plus memantine to assess feasibility and explore neurocognitive outcomes versus historical WBRT. Prior SRS or resection and prior systemic therapy are allowed with washouts; excludes primary CNS/hematologic malignancies and large (>5 cm) unresected lesions.

ClinicalTrials.gov ID: NCT05045950

UAB 2507 - Randomized Phase II Study of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

TrialFetch AI summary: Adults with up to ~20 brain metastases (each ≤4 cm), including intact lesions or postoperative cavities and even after prior WBRT, are randomized to linac-based single-isocenter SRS using either 0 mm or 2 mm PTV margins. The trial compares local control and grade ≥3 CNS toxicity at 12 months with standard SRS dosing (16–20 Gy ×1 for <2 cm; 27 Gy in 3 fractions for 2–4 cm); no investigational drugs are used.

ClinicalTrials.gov ID: NCT06857006

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

TrialFetch AI summary: Children and young adults (6–21) with recurrent primary brain tumors lacking curative options or relapsed/refractory solid tumors after ≥2 prior lines receive standard chemotherapy plus dapagliflozin, an SGLT2 inhibitor (metabolic modulation via reduced glucose/insulin and ketone shift) to assess safety/feasibility and preliminary activity. Regimens include carmustine+dapagliflozin for brain tumors and topotecan/cyclophosphamide+dapagliflozin for solid tumors, with age-based dapagliflozin dosing and close metabolic/renal monitoring due to risks such as euglycemic ketoacidosis and infections.

ClinicalTrials.gov ID: NCT05521984

A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors.

TrialFetch AI summary: Adults with CNS tumors receiving radiotherapy: recurrent/relapsed GBM (IMRT 35 Gy/2 weeks) and newly diagnosed GBM with unmethylated MGMT (IMRT 60 Gy/6 weeks) are treated with concurrent oral AZD1390, a brain-penetrant ATM kinase inhibitor radiosensitizer; the closed arm previously enrolled patients with brain metastases not suitable for SRS. Key eligibility includes KPS ≥60 and MRI suitability; exclusions include strong CYP3A4 modulators and significant comorbidities.

ClinicalTrials.gov ID: NCT03423628

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with HER2-positive metastatic solid tumors (including ERBB2-mutant) and active/progressing brain metastases not needing immediate local CNS therapy receive tucatinib (selective HER2 TKI with CNS penetration) plus ado-trastuzumab emtansine (HER2-directed antibody–drug conjugate) in 21-day cycles after prior HER2 therapy as applicable. Aims to assess intracranial response and safety; excludes patients with large/unstable brain lesions or needing urgent local therapy.

ClinicalTrials.gov ID: NCT05673928

Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma

TrialFetch AI summary: Adults with recurrent glioblastoma or gliosarcoma after prior standard brain RT (≤63 Gy), ECOG 0–2, single measurable lesion ≤6 cm, receive spectroscopic MRI-guided focal proton re-irradiation (IMPT, 35 Gy/10 fx or 40 Gy/10 fx with SIB) combined with bevacizumab (anti–VEGF-A monoclonal antibody) started before RT. Excludes multifocal disease, prior re-irradiation or bevacizumab, and lesions in regions prone to sMRI artifact.

ClinicalTrials.gov ID: NCT05284643